<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1235">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793984</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19/TCP_20_05</org_study_id>
    <nct_id>NCT04793984</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients</brief_title>
  <official_title>Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinomed Biotech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Austian Research Promotion Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Marinomed Biotech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will investigate the tolerability and efficacy of inhaled Carragelose®&#xD;
      versus saline in hospitalized COVID-19 patients. As SARS-CoV-2 replicates readily in the&#xD;
      lung, it is planed to apply Carragelose® in an inhalative form. Hospitalized COVID-19&#xD;
      patients with respiratory symptoms will inhale Inhaleen for 5 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The tolerability and efficacy of inhaled Carragelose® will be investigated in a randomized,&#xD;
      double blind, placebo-controlled trial in hospitalized COVID-19 patients.&#xD;
&#xD;
      Patients will inhale Inhaleen or Placebo 3 times a day for 7 minutes for 5 days.&#xD;
&#xD;
      The primary objective of the trial is to demonstrate that Inhaleen inhalation improves the&#xD;
      clinical status of hospitalized COVID-19 patients on day 8 compared to placebo inhalation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized placebo-controlled double blinded trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical status of subjects as expressed on the WHO-8-Category ordinal scale:</measure>
    <time_frame>day 8</time_frame>
    <description>Not hospitalized and no limitations of activities&#xD;
Not hospitalized, with limitations of activities, home oxygen requirement, or both&#xD;
Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infections-control or other nonmedical reasons)&#xD;
Hospitalized not requiring supplemental oxygen but requiring ongoing medical care related to COVID-19) or to other medical conditions)&#xD;
Hospitalized requiring any supplemental oxygen&#xD;
Hospitalized requiring non-invasive ventilation or use of high-flow oxygen devices&#xD;
Hospitalized receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cycle threshold of SARS-CoV-2 PCR·</measure>
    <time_frame>until day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>multiplex viral examination</measure>
    <time_frame>until day 15</time_frame>
    <description>NxTAG® Respiratory Pathogen Panel + SARS-CoV-2 (Luminex, Cat: X056C0470) detects and differentiates nucleic acids from SARS-CoV-2 and the following organism types and subtypes: Influenza A, Influenza A H1, Influenza A H3, Influenza B, Influenza A 2009 H1N1, Legionella pneumophila, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B, Coronavirus 229E, Coronavirus OC43, Coronavirus NL63, Coronavirus HKU1, Human Metapneumovirus, Rhinovirus/Enterovirus, Adenovirus, Parainfluenza virus 1, Parainfluenza virus 2, Parainfluenza virus 3, Parainfluenza virus 4, Human Bocavirus, Chlamydophila pneumoniae, and Mycoplasma pneumoniae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>supplemental oxygen requirement</measure>
    <time_frame>until day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified 10 point BORG scale</measure>
    <time_frame>day 1 to day 5</time_frame>
    <description>a higher score means a worse condition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Inhaleen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iota-Carrageenan inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carragelose</intervention_name>
    <description>inhalation 3 times a day</description>
    <arm_group_label>Inhaleen</arm_group_label>
    <other_name>iota-Carageenan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>inhalation 3 times a day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained before any trial related procedures are performed&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Hospitalized patients with PCR confirmed SARS-CoV-2 infection and symptom onset ≤ 10&#xD;
             days before randomization&#xD;
&#xD;
          -  Patients with respiratory COVID-19 symptoms&#xD;
&#xD;
          -  Randomization ≤ 48h from admission&#xD;
&#xD;
          -  Peripheral capillary oxygen saturation (SpO2) ≥ 90% on room air or supplemental oxygen&#xD;
             at screening&#xD;
&#xD;
          -  Patient agrees to refrain from taking other carragelose products (e.g. throat spray,&#xD;
             lozenges)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
&#xD;
          -  Persistent hypoxemia with SpO2 &lt; 90% despite supplemental oxygen of &gt; 6LO2/min at&#xD;
             screening.&#xD;
&#xD;
          -  Patients with predominantly extrapulmonary COVID-19 symptoms (e.g. gastrointestinal,&#xD;
             neurological, etc.)&#xD;
&#xD;
          -  Subjects who demonstrate respiratory and/or cardiac instability that is considered by&#xD;
             the investigator as a reason for exclusion. Additionally, any other clinically&#xD;
             significant disease that could interfere with participation in the study, with the&#xD;
             intervention being studied, or with the evaluation of symptoms. Specific exclusions&#xD;
             are asthma, immune deficiency, autoimmune disease, clinically significant&#xD;
             cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease&#xD;
             or any disease that is considered by the investigator as a reason for exclusion.&#xD;
&#xD;
          -  Known hypersensitivity or allergy to any component of the test product&#xD;
&#xD;
          -  The subject is related to any study personnel or has any other close ties or conflicts&#xD;
             of interest with the study sponsor.&#xD;
&#xD;
          -  The subject has received any investigational drug or participated in a clinical trial&#xD;
             within 4 weeks of entry to this study&#xD;
&#xD;
          -  Current medication other than oral contraception,that is considered by the&#xD;
             investigator as a reason for exclusion.&#xD;
&#xD;
          -  Pregnant/lactating women at the time of recruitment will be excluded from the study&#xD;
&#xD;
          -  Participation in another antiviral clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arschang Valipour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karl Landsteiner Society; Clinic Floridsdorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg-Christian Funk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karl Landsteiner Society, Clinic Ottakring</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Hoeppler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gesundheitsverbund Klinik Favoriten</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Unger-Manhart, PhD</last_name>
    <phone>+43226290300</phone>
    <email>nicole.unger-manhart@marinomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Prieschl-Grassauer, PhD</last_name>
    <phone>+43226290300</phone>
    <email>eva.prieschl-grassauer@marinomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gesundheitsverbund, Klinik Floridsdorf</name>
      <address>
        <city>Vienna</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arschang Valipour, MD</last_name>
      <phone>+43 1 277 00</phone>
      <phone_ext>72201</phone_ext>
      <email>arschang.valipour@gesundheitsverbund.at</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Fabikan</last_name>
      <phone>+43127700</phone>
      <phone_ext>72201</phone_ext>
      <email>hannah.fabikan@extern.gesundheitsverbund.at</email>
    </contact_backup>
    <investigator>
      <last_name>Saad Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carragelose</keyword>
  <keyword>iota-Carrageenan</keyword>
  <keyword>lung</keyword>
  <keyword>virus</keyword>
  <keyword>respiratory virus</keyword>
  <keyword>inhalation</keyword>
  <keyword>common cold</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

